To assess the association of semaglutide with incident CUD, the study population included 587,849 patients with T2D who had active medical encounters for T2D during 12/20175/2021, were for the first time prescribed semaglutide (Ozempic) or non-GLP1-1RA anti-diabetes medications (new-user design) during 12/20175/2021(index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
After the lawsuit, the FDA had temporarily paused enforcement but reaffirmed its position in December
10.1016/j.eclinm.2024.102624 12 HernandezI.SullivanS
Is there a history of tick exposure or known Lyme co-infections
However, research in this area continues with several companies exploring novel GLP-1 treatment strategies